CABA News and Press, Cabaletta Bio Inc. From 12/11/23

2023-12-11 05:58:05 ET Summary Cabaletta Bio is developing targeted cellular therapies for autoimmune diseases, including systemic lupus erythematous and myositis. Their lead program, CABA-201, is a CD19 chimeric antigen receptor (CAR) T cell therapy currently in phase 1/2 clinica...

2023-12-10 02:44:26 ET Summary Cabaletta Bio is a biotech company with promising CARTA and CAART therapies for autoimmune diseases. Their main research project, CABA-201, targets patients suffering from SLE, opening up a huge market with significant revenue potential. The comp...

Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved 7.19% on the day to $13.72. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B ...

2023-12-06 16:37:38 ET Verint Systems  ( VRNT ) +11% . ZyVersa Therapeutics ( ZVSA ) +6% . Couchbase ( BASE ) +4% . Grayscale Solana Trust  ( OTCQB:GSOL ) +4% . Cabaletta  ( CABA ) +3% . Vivid Seats ( SEAT ) ...

PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Exe...

2023-11-27 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved 7.19% on the day to $13.72. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B ...

2023-11-09 07:57:29 ET More on Cabaletta Bio Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue? Cantor starts Cabaletta at overweight, cites "strong" position in CART-T drugs Cabaletta Bio director purchases, sells shares in co...

– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical development program within rheumat...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...